Paper41255464
Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.
Zhu X and 4 others. Int J Nanomedicine, 2025. Cited by 6 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy. Papers, record 41255464. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41255464
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mouth Neoplasms | Major topic |
| Theranostic Nanomedicine | Major topic |
| Nanostructures | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Humans | |
| Drug Delivery Systems | |
| Combined Modality Therapy | |
| Biosensing Techniques | |
| Animals | |
| Photochemotherapy | |
| Genetic Therapy |
Source PubMed
References258
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40285805 | Innovative nanoparticle strategies for treating oral cancers. | Med Oncol | 2025 | https://conductscience.org/library/papers/40285805 | PubMed |
| 2 | 37547360 | Nanoplatforms: The future of oral cancer treatment. | Health Sci Rep | 2023 | https://conductscience.org/library/papers/37547360 | PubMed |
| 3 | 36971908 | Oral delivery of RNAi for cancer therapy. | Cancer Metastasis Rev | 2023 | https://conductscience.org/library/papers/36971908 | PubMed |
| 4 | 40682120 | Delivery of an ERK inhibitor using bioactive lipid nanoparticles reduces angiogenesis and prevents oral squamous cell carcinoma development. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40682120 | PubMed |
| 5 | 34976214 | Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. | Theranostics | 2022 | https://conductscience.org/library/papers/34976214 | PubMed |
| 6 | 36079307 | Graphene Nanostructures by Pulsed Laser Ablation in Liquids: A Review. | Materials (Basel) | 2022 | https://conductscience.org/library/papers/36079307 | PubMed |
| 7 | 39902172 | Harnessing nanotechnology for cancer treatment. | Front Bioeng Biotechnol | 2024 | https://conductscience.org/library/papers/39902172 | PubMed |
| 8 | 39501968 | Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications. | Adv Healthc Mater | 2025 | https://conductscience.org/library/papers/39501968 | PubMed |
| 9 | 36923400 | The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles. | Front Immunol | 2023 | https://conductscience.org/library/papers/36923400 | PubMed |
| 10 | 37971722 | Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. | JAMA Oncol | 2024 | https://conductscience.org/library/papers/37971722 | PubMed |
| 11 | 39467056 | Protecting Against Postsurgery Oral Cancer Recurrence with an Implantable Hydrogel Vaccine for In Situ Photoimmunotherapy. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39467056 | PubMed |
| 12 | 40075499 | Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40075499 | PubMed |
| 13 | 32984600 | Prospects of nanodentistry for the diagnosis and treatment of maxillofacial pathologies and cancers. | Heliyon | 2020 | https://conductscience.org/library/papers/32984600 | PubMed |
| 14 | 36568302 | Editorial: Synthesis, functionalization, and clinical translation of pharmaceutical biomaterials. | Front Bioeng Biotechnol | 2022 | https://conductscience.org/library/papers/36568302 | PubMed |
| 15 | 33096430 | One-step quantification of salivary exosomes based on combined aptamer recognition and quantum dot signal amplification. | Biosens Bioelectron | 2021 | https://conductscience.org/library/papers/33096430 | PubMed |
| 16 | 33462277 | Graphene oxide loaded with tumor-targeted peptide and anti-cancer drugs for cancer target therapy. | Sci Rep | 2021 | https://conductscience.org/library/papers/33462277 | PubMed |
| 17 | 38275722 | The Golgi Apparatus as an Anticancer Therapeutic Target. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/38275722 | PubMed |
| 18 | 37628860 | Current Advances in the Biomedical Applications of Quantum Dots: Promises and Challenges. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37628860 | PubMed |
| 19 | 35057015 | Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35057015 | PubMed |
| 20 | 39634304 | Carbon nanomaterials for phototherapy. | Nanophotonics | 2022 | https://conductscience.org/library/papers/39634304 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42866938 | TOMM5 is associated with oral cancer progression: a multi-omics analysis from single-cell atlas to in vitro validation. | Future Sci OA | 2026 | https://conductscience.org/library/papers/42866938 | PubMed |
| 42449634 | Current Trends in Diagnosis and Early Monitoring of Oral Cavity Cancer: Techniques and Biomarkers. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449634 | PubMed |
| 41769336 | Metabolic crosstalk between oral microbiota and the host in OSCC: emerging roles of microbial metabolites in tumor initiation and progression. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/41769336 | PubMed |
| 41465540 | Holography Meets Theranostics: DFT/TDDFT Insights into Ru-NO@M20 (M = Au, Ag) and Ru-NO@Au10Ag10(Pc) Nanohybrids as Phase-Switchable Molecular Devices. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465540 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41255464
GET https://conductscience.org/api/papers/v1/41255464/references?page=2